NVS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$155.37median target· current $156.17 (-0.5%)12 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio23.59Forward 17.45
EPS (TTM)$6.62-17.0% YoY
Profit margin22.5%HEALTHCARE
Market cap$296.80BMega cap
Valuation
- Forward P/E
- 17.45
- PEG ratio
- 3.56
- P/B
- 7.14
- P/S (TTM)
- 5.24
- EV/EBITDA
- 15.13
Profitability & growth
- ROE (TTM)
- 30.3%
- Operating margin
- 34.6%
- Revenue growth YoY
- 0.8%
- Dividend yield
- 3.0%
- Beta
- 0.49
Last earnings
Jul 21, 2026 · Estimate $2.20 · Reported $2.41
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Novartis AG ADR
Company profileNovartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- LICHTSTRASSE 35, BASEL, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$296.80B
Shares outstanding$1.90B
52W high$165.43
52W low$110.13
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent